Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-10-22 Legal Proceedings Report
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides drar tillbaka Pepaxto®, minskar organisationen och fokuserar på R&D
Legal Proceedings Report Classification · 1% confidence The document is a press release dated October 22, 2021, titled "Oncopeptides drar tillbaka Pepaxto®, minskar organisationen och fokuserar på R&D" (Oncopeptides withdraws Pepaxto®, reduces organization and focuses on R&D). It announces a major strategic shift, the withdrawal of a drug from the US market following FDA feedback, organizational restructuring, and a delay of the Q3 report. It also invites stakeholders to a webcast and Q&A session regarding these developments. This type of announcement, detailing significant corporate actions, strategic changes, and operational updates, is best classified as a general Regulatory Filing (RNS) or potentially a Call Transcript (CT) if the webcast was the primary focus, but since it's a formal press release announcing major news, RNS is the most appropriate general regulatory category for significant, non-standard disclosures. It is not a specific financial report (10-K, IR, ER) or a management/board change (MANG). Given the nature of the announcement (drug withdrawal, restructuring), it is a significant regulatory disclosure.
2021-10-22 Swedish
Oncopeptides withdraws Pepaxto®[ ]in US, scale down organization and focus on R&D
Regulatory Filings Classification · 1% confidence The document is a press release dated October 22, 2021, announcing a major strategic shift: the withdrawal of Pepaxto® from the US market following FDA feedback on the OCEAN study, leading to a significant scale-down of operations and refocus on R&D. It also mentions the postponement of the Q3 report and invites participation in a conference call. This type of announcement, detailing significant corporate actions, strategic changes, and operational restructuring based on regulatory outcomes, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it contained preliminary financial data, but since it's primarily a strategic/regulatory event announcement, RNS is the most appropriate general category for significant, non-standard corporate news that doesn't fit the other specific codes (like DIV, CAP, or MANG). Given the content is a major corporate announcement about regulatory interaction and strategic pivot, RNS (Regulatory Filings/General Announcement) serves as the best fit among the provided options, as it is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA).
2021-10-22 English
Oncopeptides’ CFO Anders Martin-Löf will leave the company
Board/Management Information Classification · 1% confidence The document is a press release dated October 15, 2021, announcing that the company's CFO, Anders Martin-Löf, will be leaving the company. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The filing code for this category is MANG. The document is not a formal regulatory report like a 10-K or IR, nor is it a general regulatory filing (RNS) or a report publication announcement (RPA), as it is substantive news about personnel change.
2021-10-15 English
Oncopeptides CFO Anders Martin-Löf kommer att lämna bolaget
Board/Management Information Classification · 1% confidence The document is a press release dated October 15, 2021, titled "Oncopeptides CFO Anders Martin-Löf kommer att lämna bolaget" (Oncopeptides CFO Anders Martin-Löf will leave the company). This explicitly announces a change in senior management (the CFO). According to the definitions, announcements of changes in the company's board of directors or senior management fall under the Board/Management Information category (MANG). The document is short and serves as an announcement, not a comprehensive report like a 10-K or IR.
2021-10-15 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT Q2 2021' (Interim Report Q2 2021) and contains comprehensive financial statements, including income statements, cash flow data, and management commentary for the period ending June 30, 2021. It provides detailed analysis of business performance, clinical trial updates, and financial results, which fits the definition of an Interim/Quarterly Report (IR). Q2 2021
2021-08-19 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT Q2 2021' and contains comprehensive financial statements, including net sales, operating loss, loss per share, and cash flow data for the period of April-June 2021. It also includes a 'Letter from the CEO' and detailed sections on financial overview, commercial activities, and clinical development. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q2 2021
2021-08-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.